ResearchMoz

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease

GBI Research
Published Date » 2013-05-03
No. Of Pages » N/A

GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019. 

The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period. 

The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006. Demand for immunoglobulin products continues to increase due to growing disease awareness and therapeutic usage in a wide range of therapeutic areas. Immunology and neurology are the disciplines that use the most immunoglobulins, while PI and CIDP are the top indications. 

Geographically, the US is the largest market, commanding a share of over 70% of the global market. 11 new products have been approved in the US since 2006, but as many are for PI or ITP, immunoglobulin usage in the US remains off-label for all other indications. Baxter, CSL Behring, and Grifols continue to command the top ranks in terms of revenue, and recent approvals of Subcutaneous Immunoglobulins (SCIGs) in the US and Europe will further boost market growth.

Scope

  • Annualized market data for the immunoglobulin market from 2006 to 2012 and forecast to 2019
  • Analysis of the seven key therapeutic segments: PI, CIDP, MMN, MG, CLL, GBS and ITP
  • Analysis of the immunoglobulins markets in the leading global geographies: the US, the top five European countries, and Japan
  • Market characterization of the immunoglobulin market, covering size, revenue analysis by geography, annual cost of therapy, and epidemiology
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of key marketed products, approved indications, and safety and efficacy profiles
  • Coverage of the pipeline molecules in various phases of drug development
  • Competitive profiling of the leading companies: Baxter, Biotest, Bio Products Laboratory, CSL Behring, Grifols, and Octapharma
  • Key M&A activity and licensing agreements between 2012 and mid-2013 in the global immunoglobulin market
  • Overview of the immunoglobulin markets in Asia-Pacific and China, covering regulations, key players and marketed products

Reasons to Buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market-entry and market-expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Develop key strategic initiatives by understanding the key focus areas of the leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Immunoglobulins Market to 2019 - Introduction
2.1 Overview

3 Immunoglobulins Market to 2019 - Market Overview
3.1 Revenue
3.2 Annual Cost of Therapy
3.3 Immunoglobulins Market Drivers and Restraints
3.3.1 Market Drivers
3.3.2 Restraints

4 Immunoglobulins Market to 2019 - Geographical Landscape
4.1 US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.2 Top Five European Countries
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy

5 Immunoglobulins Market to 2019 - Therapeutic Landscape
5.1 Main Therapeutic Indications
5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage - US
5.1.2 Indications for Intravenous Immunoglobulin Usage - Europe
5.1.3 Guidelines for Intravenous Immunoglobulin Usage - UK
5.1.4 Indications for Intravenous Immunoglobulin Usage - Japan
5.2 Revenue Share for the Major Therapeutic Indications
5.3 Primary Immunodeficiency Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Epidemiology
5.3.5 Current Use
5.3.6 Geographical Segmentation
5.4 Guillain-Barré Syndrome Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Epidemiology
5.4.5 Current Use for Therapies
5.4.6 Geographical Segmentation
5.5 Chronic Lymphocytic Leukemia Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Epidemiology
5.5.5 Current Use
5.5.6 Geographical Segmentation
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Annual Cost of Therapy
5.6.4 Epidemiology
5.6.5 Current Use
5.6.6 Geographical Segmentation
5.7 Myasthenia Gravis Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost of Therapy
5.7.4 Epidemiology
5.7.5 Current Use
5.7.6 Geographical Segmentation
5.8 Multifocal Motor Neuropathy Market
5.8.1 Introduction
5.8.2 Revenue
5.8.3 Annual Cost of Therapy
5.8.4 Epidemiology
5.8.5 Current Use
5.8.6 Geographical Segmentation
5.9 Idiopathic Thrombocytopenic Purpura
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost of Therapy
5.9.4 Epidemiology
5.9.5 Current Use
5.9.6 Geographical Segmentation

6 Immunoglobulins Market to 2019 - Profiles of Marketed Products
6.1 Overview
6.2 Privigen
6.2.1 Overview
6.2.2 Approved Indications
6.2.3 Safety
6.2.4 Efficacy
6.3 Gammagard S/D
6.3.1 Overview
6.3.2 Approved Indications
6.3.3 Safety
6.3.4 Efficacy
6.4 Gammagard Liquid
6.4.1 Overview
6.4.2 Approved Indications
6.4.3 Safety
6.4.4 Efficacy
6.5 Octagam 5%
6.5.1 Overview
6.5.2 Approved Indications
6.5.3 Safety
6.5.4 Efficacy
6.6 Flebogamma 10% DIF
6.6.1 Overview
6.6.2 Approved Indications
6.6.3 Safety
6.6.4 Efficacy
6.7 Gamunex-C
6.7.1 Overview
6.7.2 Approved Indications
6.7.3 Safety
6.7.4 Efficacy
6.8 Gammaplex
6.8.1 Overview
6.8.2 Approved Indications
6.8.3 Safety
6.8.4 Efficacy
6.9 HyQvia
6.9.1 Overview
6.9.2 Approved Indications
6.9.3 Safety
6.9.4 Efficacy
6.10 Bivigam
6.10.1 Overview
6.10.2 Approved Indications
6.10.3 Safety
6.10.4 Efficacy

7 Immunoglobulins Market to 2019 - Pipeline Analysis
7.1 Research and Development Pipeline
7.2 Major Pipeline Product Profiles
7.2.1 IVIG3I Grifols 10%
7.2.2 RI-002 (IVIG)

8 Immunoglobulins Market to 2019 - Competitive Landscape
8.1 Baxter International Inc.
8.1.1 Business Description
8.1.2 Recent Developments
8.2 Biotest Pharmaceuticals
8.2.1 Business Description
8.2.2 Recent Developments
8.3 Bio Products Laboratory Ltd.
8.3.1 Business Description
8.3.2 Recent Developments
8.4 CSL Behring Limited
8.4.1 Business Description
8.4.2 Recent Developments
8.5 Grifols S.A.
8.5.1 Business Description
8.5.2 Recent Developments
8.6 Octapharma AG
8.6.1 Business Description
8.6.2 Recent Developments

9 Immunoglobulins Market to 2019 - M&A and Licensing Deals Landscape
9.1 M&A Deals
9.1.1 Grifols Buys 60% of Progenika Biopharma
9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience
9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada’s Cangene
9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro
9.2 R&D Licensing Agreements
9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil

10 Immunoglobulins Market to 2019 - Asia-Pacific and China
10.1 India
10.1.1 Overview
10.1.2 Regulatory Landscape
10.1.3 National Institute for Biologicals
10.1.4 Marketed Products
10.1.5 Product Profiles
10.1.6 Company Profiling
10.2 China
10.2.1 Overview
10.2.2 Regulatory Information
10.2.3 Marketed Products
10.2.4 Company Profiling
10.3 Australia
10.3.1 Overview
10.3.2 Regulatory Landscape
10.3.3 Marketed Products
10.3.4 Product Profiles
10.3.5 Company Profiling

11 Global Immunoglobulins Market: Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 References
11.4 Research Methodology
11.4.1 Coverage
11.4.2 Secondary Research
11.4.3 Primary Research
11.4.4 Expert Panel Validation
11.5 Contact Us
11.6 Disclaimer

List of Tables


Table 1: Immunoglobulins Market, Top Seven Markets, Revenue ($bn), 2006-2012
Table 2: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2012-2019
Table 3: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy ($), 2006-2012
Table 4: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2012-2019
Table 5: Immunoglobulins Market, US, Revenue ($bn), 2006-2012
Table 6: Immunoglobulins Market, US, Revenue Forecast ($bn), 2012-2019
Table 7: Immunoglobulins Market, US, Annual Cost of Therapy ($), 2006-2012
Table 8: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2012-2019
Table 9: Immunoglobulins Market, Top Five European Countries, Revenue ($m), 2006-2012
Table 10: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019
Table 11: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2012
Table 12: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2012-2019
Table 13: Immunoglobulins Market, Japan, Revenue ($m), 2006-2012
Table 14: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2012-2019
Table 15: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2012
Table 16: Immunoglobulins Market, Japan, Annual Cost of Therapy Forecast ($), 2012-2019
Table 17: Immunoglobulins Market, US, Approved Indications for IVIG Usage, 2012
Table 18: Immunoglobulins Market, EU, Indicated Conditions for IVIG Usage, 2012
Table 19: Immunoglobulins Market, UK, Guidelines for IVIG Usage, 2012
Table 20: Immunoglobulins Market, Top Seven Markets, PI, Revenue ($bn), 2006-2012
Table 21: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2012-2019
Table 22: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy ($), 2006-2012
Table 23: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2012-2019
Table 24: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology, 2006-2012
Table 25: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology Forecast, 2012-2019
Table 26: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue ($m), 2006-2012
Table 27: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2012-2019
Table 28: Immunoglobulins Market, Top Seven Markets, GBS, Revenue ($m), 2006-2012
Table 29: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2012-2019
Table 30: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy ($), 2006-2012
Table 31: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2012-2019
Table 32: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology, 2006-2012
Table 33: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology Forecast, 2012-2019
Table 34: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue ($m), 2006-2012
Table 35: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2012-2019
Table 36: Immunoglobulins Market, Top Seven Markets, CLL, Revenue ($m), 2006-2012
Table 37: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2012-2019
Table 38: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy ($), 2006-2012
Table 39: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2012-2019
Table 40: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology, 2006-2012
Table 41: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology Forecast, 2012-2019
Table 42: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue ($m), 2006-2012
Table 43: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2012-2019
Table 44: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue ($m), 2006-2012
Table 45: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2012-2019
Table 46: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy ($), 2006-2012
Table 47: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2012-2019
Table 48: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology, 2006-2012
Table 49: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology Forecast, 2012-2019
Table 50: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue ($m), 2006-2012
Table 51: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2012-2019
Table 52: Immunoglobulins Market, Top Seven Markets, MG, Revenue ($m), 2006-2012
Table 53: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2012-2019
Table 54: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy ($), 2006-2012
Table 55: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2012-2019
Table 56: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology, 2006-2012
Table 57: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology Forecast, 2012-2019
Table 58: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue ($m), 2006-2012
Table 59: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2012-2019
Table 60: Immunoglobulins Market, Top Seven Markets, MMN, Revenue ($m), 2006-2012
Table 61: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2012-2019
Table 62: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy ($), 2006-2012
Table 63: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2012-2019
Table 64: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology, 2006-2012
Table 65: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology Forecast, 2012-2019
Table 66: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue ($m), 2006-2012
Table 67: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2012-2019
Table 68: Immunoglobulins Market, Top Seven Markets, ITP, Revenue ($m), 2006-2012
Table 69: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2012-2019
Table 70: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy ($), 2006-2012
Table 71: Immunoglobulins Market, Top Seven Markets, ITP, Annual of Cost Therapy Forecast ($),
2012-2019
Table 72: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology, 2006-2012
Table 73: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology Forecast, 2012-2019
Table 74: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue ($m), 2006-2012
Table 75: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2012-2019
Table 76: Immunoglobulins Market, US, FDA-Approved IVIG Products by Therapeutic Indication,
1994-2013
Table 77: Immunoglobulins Market, Top Five European Countries, EMA-Approved IVIG Products by Therapeutic Indication, 2004-2013
Table 78: Immunoglobulins Market, Global, Phase III Pipeline Molecules, 2013
Table 79: Immunoglobulins Market, Global, Alzheimer’s Disease, Pipeline Molecules, 2013
Table 80: Immunoglobulins Market, Grifols, Global, Marketed Immunoglobulin Products, 2013
Table 81: Immunoglobulins Market, India, PI, Marketed Products, 2013
Table 82: Immunoglobulins Market, India, GBS, Marketed Products, 2013
Table 83: Immunoglobulins Market, India, CLL, Marketed Products, 2013
Table 84: Immunoglobulins Market, India, CIDP, Marketed Products, 2013
Table 85: Immunoglobulins Market, India, ITP, Marketed Products, 2013
Table 86: Immunoglobulins Market, India, Reliance Life Sciences, Key Pipeline Products, 2012-2013
Table 87: Immunoglobulins Market, India, Zydus Cadila, Key Marketed Products, 2012-2013
Table 88: Immunoglobulins Market, India, Sun Pharmaceuticals, Generic Versions of Key Marketed Products, 2012-2013
Table 89: Immunoglobulins Market, China, Blood and Blood Products Industry, 1985-2012
Table 90: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011
Table 91: Immunoglobulins Market, Australia, Marketed Products, CIDP, 2013
Table 92: Immunoglobulins Market, Australia, Marketed Products, CLL, 2013
Table 93: Immunoglobulins Market, Australia, Marketed Products, GBS, 2013
Table 94: Immunoglobulins Market, Australia, Marketed Products, ITP, 2013
Table 95: Immunoglobulins Market, Australia, Marketed Products, PI, 2013

List of Figures


Figure 1: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2006-2019
Figure 2: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 3: Immunoglobulins Market, US, Revenue Forecast ($bn), 2006-2019
Figure 4: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 5: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019
Figure 6: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2019
Figure 7: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2006-2019
Figure 8: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2019
Figure 9: Immunoglobulins Market, Top Seven Markets, Market Share by Therapeutic Indication (%), 2012
Figure 10: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2006-2019
Figure 11: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 12: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2006-2019
Figure 13: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2006-2019
Figure 14: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 15: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2006-2019
Figure 16: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2006-2019
Figure 17: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 18: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2006-2019
Figure 19: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2006-2019
Figure 20: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 21: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2006-2019
Figure 22: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2006-2019
Figure 23: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 24: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2006-2019
Figure 25: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2006-2019
Figure 26: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 27: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2006-2019
Figure 28: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2006-2019
Figure 29: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 30: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2006-2019
Figure 31: Immunoglobulins Market, US, FDA-Approved Products by Therapeutic Indication, 2003-2013
Figure 32: Immunoglobulins Market, Australia, IVIG Issued (g/1,000 population), 2006-2012
Figure 33: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011

Upcoming Reports:

Electrophysiology (EP) Devices Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Increasing incidences of sudden cardiac arrests, growth in the use of robotic guided catheters in diagnostic procedures, and increase in the arrhythmia population are some of the major factors driving the growth of electrophysiology devices industry. Need to reduce diagnostic procedure time, improve success rate, and reduce human exposure to radiations is driving technological innovations in this industry.  The global electrophysiology (EP) devices market is expected to witness significant growth rate and reach USD 4.4 billion by 2015 at a CAGR of 9.7% during the forecast...
Cogeneration Equipment Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Increasing fuel costs and economic recession have encouraged demand for more efficient power cogeneration equipments that can improve profitability. Technological trends in the cogeneration equipment market emphasize on increasing efficiency, portability, and quality of these equipments. Product innovations and sustained research and developments in this field are some important factors contributing to the growth of cogeneration equipment market. One of the major challenges faced by this market is its inconsistency in orders. Many manufacturers are finding it difficult to deal with...
Uterine Cancer Therapies and Diagnostic Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Uterine cancer is a cancer of uterus and is classified into the following four types, namely uterine sarcomas, endometrial cancer, cervical cancer and gestational trophoblastic disease. These cancers arise from malignancies of connective tissues, endometrium and cervix uteri of the uterus. Uterine cancers are the fourth most common cancers among women overall. According to American Cancer Society (ACS), uterine sarcoma accounts for 5% of the total global uterine cancer cases whereas endometrial cancer is most prevalent form of uterine cancer.  Both of these cancers can be...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...